**Charles W. Gollmar,**

*Acting Associate Director for Policy Planning and Evaluation, Centers for Disease Control and Prevention (CDC).*

[FR Doc. 98–11823 Filed 5–4–98; 8:45 am]

**BILLING CODE 4163–18–P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### Centers for Disease Control and Prevention

### Safety and Occupational Health Study Section NIOSH Meeting

In accordance with section 10(a)(2) of the Federal Advisory Committee Act (Pub. L. 92–463), the Centers for Disease Control and Prevention (CDC) announces the following committee meeting:

*Name:* Safety and Occupational Health Study Section, National Institute for Occupational Safety and Health (NIOSH).

*Times and dates:* 8 a.m.–5:30 p.m., June 18, 1998. 8 a.m.–5:30 p.m., June 19, 1998.

*Place:* Embassy Suites Hotel, 1900 Diagonal Road, Alexandria, Virginia 22314.

*Status:* Open 8 a.m.–8:30 a.m., June 18, 1998; Closed 8:30 a.m.–5:30 p.m., June 18, 1998; Closed 8 a.m.–5:30 p.m., June 19, 1998.

*Purpose:* The Safety and Occupational Health Study Section will review, discuss, and evaluate grant application(s) in response to the Institute's standard grants review and funding cycles pertaining to research issues in occupational safety and health and allied areas.

It is the intent of NIOSH to support broad-based research endeavors in keeping with the Institute's program goals which will lead to improved understanding and appreciation for the magnitude of the aggregate health burden associated with occupational injuries and illnesses, as well as to support more focused research projects which will lead to improvements in the delivery of occupational safety and health services and the prevention of work-related injury and illness. It is anticipated that research funded will promote these program goals.

*Matters to be discussed:* The meeting will convene in open session from 8–8:30 a.m., on June 18, 1998, to address matters related to the conduct of Study Section business. The remainder of the meeting will proceed in closed session. The purpose of the closed sessions is for the Safety and Occupational Health Study Section to consider safety and occupational health related grant applications. These portions of the meeting will be closed to the public in accordance with provisions set forth in section 552(c) (4) and (6), title 5 U.S.C., and the Determination of the Associate Director for Management and Operations, CDC, pursuant to Public Law 92–463.

Agenda items are subject to change as priorities dictate.

*Contact person for more information:* Pervis C. Major, Ph.D., Scientific Review Administrator, Office of Extramural Coordination and Special Projects, Office of the Director, NIOSH, 1095 Willowdale Road, Morgantown, West Virginia 26505. Telephone 304/285–5979.

Dated: April 28, 1998.

**Nancy C. Hirsch,**

*Acting Director, Management Analysis and Services Office, Centers for Disease Control and Prevention (CDC).*

[FR Doc. 98–11820 Filed 5–4–98; 8:45 am]

**BILLING CODE 4163–19–P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### Food and Drug Administration

**[Docket No. 96F–0348]**

### MacMillan Bloedel, Ltd.; Withdrawal of Food Additive Petition

**AGENCY:** Food and Drug Administration, HHS.

**ACTION:** Notice.

**SUMMARY:** The Food and Drug Administration (FDA) is announcing the withdrawal, without prejudice to a future filing, of a food additive petition (FAP 6B4520) proposing that the food additive regulations be amended to provide for the safe use of ethylene glycol as a component of a pulp bleaching medium used in the manufacture of paper and paperboard intended for use in contact with food.

**FOR FURTHER INFORMATION CONTACT:** Andrew J. Zajac, Center for Food Safety and Applied Nutrition (HFS–215), Food and Drug Administration, 200 C St. SW., Washington, DC 20204, 202–418–3095.

**SUPPLEMENTARY INFORMATION:** In a notice published in the **Federal Register** of October 7, 1996 (61 FR 52454), FDA announced that a food additive petition (FAP 6B4520) had been filed by MacMillan Bloedel, Ltd., c/o Camplong & Associates, Inc., P.O. Box 238, Schomberg, ON L0G 1T0, Canada. The petition proposed to amend the food additive regulations in § 176.170 *Components of paper and paperboard in contact with aqueous and fatty foods* (21 CFR 176.170) to provide for the safe use of ethylene glycol as a pulp bleaching agent for paper and paperboard intended for use in contact with food. Upon further review, FDA has determined that the petition proposed the use of ethylene glycol as a component of a pulp bleaching medium used in the manufacture of food-contact paper and paperboard. MacMillan Bloedel, Ltd., has now withdrawn the petition without prejudice to a future filing (21 CFR 171.7).

Dated: April 10, 1998.

**Laura M. Tarantino,**

*Acting Director, Office of Premarket Approval, Center for Food Safety and Applied Nutrition.*

[FR Doc. 98–11805 Filed 5–4–98; 8:45 am]

**BILLING CODE 4160–01–F**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### Food and Drug Administration

### Vaccines and Related Biological Products Advisory Committee; Notice of Meeting

**AGENCY:** Food and Drug Administration, HHS.

**ACTION:** Notice.

This notice announces a forthcoming meeting of a public advisory committee of the Food and Drug Administration (FDA). At least one portion of the meeting may be closed to the public.

*Name of Committee*: Vaccines and Related Biological Products Advisory Committee.

*General Function of the Committee*: To provide advice and recommendations to the agency on FDA regulatory issues.

*Date and Time*: The meeting will be held on May 26 and 27, 1998, 8 a.m. to 5:45 p.m.

*Location*: Holiday Inn, Versailles Ballrooms I and II, 8120 Wisconsin Ave., Bethesda, MD.

*Contact Person*: Nancy T. Cherry or Denise H. Royster, Center for Biologics Evaluation and Research (HFM–21), Food and Drug Administration, 1401 Rockville Pike, Rockville, MD 20852, 301–827–0314, or FDA Advisory Committee Information Line, 1–800–741–8138 (301–443–0572 in the Washington, DC area), code 12391. Please call the Information Line for up-to-date information on this meeting.

*Agenda*: The committee will: (1) Consider the safety and efficacy of a new vaccine from SmithKline for the prevention of Lyme disease; (2) consider the safety and efficacy of a live, oral, attenuated vaccine for the prevention of cholera; and (3) discuss issues relating to the potential inclusion of a boxed warning on the package insert for live polio virus vaccine.

*Procedure*: On May 26 and 27, 1998, from 9 a.m. to 5:45 p.m., the meeting is open to the public. Interested persons may present data, information, or views, orally or in writing, on issues pending before the committee. Written submissions may be made to the contact person by May 19, 1998. Oral

presentations from the public will be scheduled between approximately 9 a.m. and 9:15 a.m., and between approximately 3:30 p.m. and 3:45 p.m., on May 26, 1998, and between approximately 9 a.m. and 9:15 a.m., and between approximately 1:30 p.m. and 1:45 p.m., and between approximately 3:30 p.m. and 3:45 p.m., on May 27, 1998. Time allotted for each presentation may be limited. Those desiring to make formal oral presentations should notify the contact person before May 19, 1998, and submit a brief statement of the general nature of the evidence or arguments they wish to present, the names and addresses of proposed participants, and an indication of the approximate time requested to make their presentation.

*Closed Committee Deliberations*: On May 26 and 27, 1998, from 8 a.m. to 9 a.m., the meeting will be closed to permit discussion and review of trade secret and/or confidential information (5 U.S.C. 552b(c)(4)). These portions of the meeting will be closed to discuss pending investigational new drug applications or pending product licensing applications.

Notice of this meeting is given under the Federal Advisory Committee Act (5 U.S.C. app. 2).

Dated: April 28, 1998.

**Michael A. Friedman,**

*Deputy Commissioner for Operations.*

[FR Doc. 98–11806 Filed 5–4–98; 8:45 am]

BILLING CODE 4160–01–F

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### Food and Drug Administration

**[Docket No. 98D–0149]**

### Guidance for Industry on National Uniformity for Nonprescription Drugs—Ingredient Listing for OTC Drugs; Availability; Clarification

**AGENCY:** Food and Drug Administration, HHS.

**ACTION:** Notice; clarification.

**SUMMARY:** The Food and Drug Administration (FDA) is clarifying an administrative error relating to a notice that appeared in the **Federal Register** of April 9, 1998 (63 FR 17429). The notice announced the availability of a guidance for industry entitled ''National Uniformity for Nonprescription Drugs—Ingredient Listing for OTC Drugs.'' The agency displayed the incorrect draft of the guidance. This document clarifies that error.

**FOR FURTHER INFORMATION CONTACT:** Thomas C. Kuchenberg, Center for Drug Evaluation and Research (HFD–7), Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, 301–594–2041.

**SUPPLEMENTARY INFORMATION:** In the **Federal Register** of April 9, 1998 (63 FR 17429), FDA published a notice announcing the availability of a guidance for industry entitled ''National Uniformity for Nonprescription Drugs—Ingredient Listing for OTC Drugs.'' The agency, however, inadvertently put on display a working draft of the guidance dated February 1998, rather than the version the agency intends to implement, which is dated April 1998. This notice clarifies that error by announcing the availability of the April 1998 version of the guidance document and by withdrawing the February 1998 draft. Additionally, on February 19, 1998, FDA inadvertently put the working draft dated February 1998 on the Internet at http://www.fda.gov/cder/guidance/index.htm. The agency intends to replace the working draft that is on the Internet with the April 1998 version in the near future.

Dated: April 27, 1998.

**William K. Hubbard,**

*Associate Commissioner for Policy Coordination.*

[FR Doc. 98–11841 Filed 5–4–98; 8:45 am]

BILLING CODE 4160–01–F

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### National Institutes of Health

### Proposed Collection; Comment Request; Responsibility of Applicants for Promoting Objectivity in Research for Which Public Health Service (PHS) Funding is Sought

**SUMMARY:** In compliance with the requirement of Section 3506(c)(2)(A) of the Paperwork Reduction Act of 1995, for opportunity for public comment on proposed data collection projects, the Office of the Director (OD), the National Institutes of Health (NIH) will publish periodic summaries of proposed projects to be submitted to the Office of Management and Budget (OMB) for review and approval.

**Proposed Collection**

*Title:* Responsibility of Applicants for Promoting Objectivity in Research for Which Public Health Service (PHS) Funding is Sought: 42 CFR Part 50; 45 CFR Part 94. *Type of Information Collection Request:* Extension of OMB No. 0925–0417, expiration date 09/30/98. *Need and Use of Information Collection:* This is a request for OMB approval for the information collection and recordkeeping requirements contained in the final rule 42 CFR Part 50 and 45 CFR Part 94. The purpose of the regulations is to protect the objectivity with which PHS-funded research is conducted. The regulations require disclosure of financial interests related to PHS-funded research by personnel who have decision-making responsibilities that could affect the outcome of the research. *Frequency of Response:* On occasion. *Affected Public:* Individuals or households; Business or other for-profit; Not-for-profit institutions; State, Local or Tribal Government. *Type of Respondents:* Any public or private entity or organization. The annual reporting burden is as follows: *Estimated Number of Respondents:* 57,235; *Estimated Number of Responses per Respondent:* 10; *Average Burden Hours per Response:* 20; and *Estimated Total Annual Burden Hours Requested:* 171,110. The annualized costs to respondents is estimated at: $5,068,850. There are no Capital Costs, Operating Costs and/or Maintenance Costs to report.

**Request For Comments**

Written comments and/or suggestions from the public and affected agencies should address one or more of the following points: (1) Evaluate whether the proposed collection of information is necessary for the proper performance of the function of the agency, including whether the information will have practical utility; (2) Evaluate the accuracy of the agency's estimate of the burden of the proposed collection of information, including the validity of the methodology and assumptions used; (3) Enhance the quality, utility, and clarity of the information to be collected; and (4) Minimize the burden of the collection of information on those who are to respond, including the use of appropriate automated, electronic, mechanical, or other technological collection techniques or other forms of information technology.

**FOR FURTHER INFORMATION CONTACT:**

To request more information on the proposed project or to obtain a copy of the data collection plans and instruments, contact: Thomas F. McCormack, Ph.D., Assistant Grant's Policy Officer, Office of Extramural Research, Office of Policy for Extramural Research Administration, 6701 Rockledge Drive, Bethesda, MD 20892, or call non-toll-free number (301) 435–0935 or E-mail your request,